Dihexa

Dihexa (Angiotensin IV analogue) is a small-molecule peptidomimetic. The HEIVE catalog describes it as: Extremely potent synaptogenic activity in rodents. Essentially no human safety data exists. It is also known as PNB-0408 and N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.

HEIVE groups Dihexa under neuroplasticity, learning, memory, focus and mental clarity. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

No matching FDA product was identified for Dihexa under the searched names in the October 6, 2026 Drugs@FDA snapshot. This name search does not establish worldwide approval status or exclude differently named products. FDA describes safety concerns or insufficient safety information for the corresponding substance on its compounding-risk page; that listing is not a drug approval.

• FDA product data (October 6, 2026)
• FDA compounding safety information

The HEIVE editorial risk summary for Dihexa lists: Unknown. Anecdotal reports of headache and irritability. Longer-term concerns: Unknown, and the potency is the reason to care. Uncontrolled synaptogenesis is not obviously good. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Dihexa has no single onset time established by this catalog. The editorial timeline starts with “Days 1–14”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Dihexa: No established human dose. Forum figures are guesses. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Dihexa as having limited evidence. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists oral or topical for Dihexa. A listed form is not evidence of an approved or effective treatment.

Preparation of Dihexa depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Dihexa depends on the specific formulation (injectable, oral and topical in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Dihexa: No data. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Dihexa and Semax share the catalog categories focus, memory and mental clarity. Dihexa: Extremely potent synaptogenic activity in rodents. Essentially no human safety data exists. Semax: A Russian-registered nootropic used clinically for stroke recovery; raises BDNF in animal and some human work. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Semax

The HEIVE editorial summary highlights: Nothing yet — there is not enough human data to be surprised by. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.